SIGNATOPE GMBH

Their core work

Signatope is a German biotech SME in Reutlingen that develops and performs bioanalytical assays for safety biomarkers — the laboratory tests used to detect organ damage caused by drugs or industrial chemicals. They supply pharmaceutical developers and regulatory science consortia with translational biomarker measurements that bridge animal studies and human clinical trials. Within H2020 they contributed this niche assay capability to two major safety-science consortia covering drug development and chemical risk assessment. They function as a specialist measurement provider rather than a broad research lab.

What they specialise in

How they've shifted over time

Their first H2020 engagement (TransBioLine, 2019) was tightly framed around drug safety and biomarker qualification — classic pharma-focused translational science. From 2021 onwards, with RISK-HUNT3R, the same assay expertise was applied to chemical risk assessment, bringing in vocabulary absent from earlier work: exposure modelling, toxicokinetics, AOP networks and systems toxicology. The trend is a widening of their addressable market from pharma-only safety into broader regulatory toxicology using non-animal methods.

They are positioning their biomarker platform beyond pharma into regulatory chemical safety, which makes them increasingly relevant for chemicals, cosmetics and food-contact safety consortia, not just drug developers.

How they like to work

Signatope joins as a specialist participant rather than leading consortia — neither H2020 project had them as coordinator. They work inside very large multi-country safety-science consortia (67 unique partners across 14 countries from just two projects), suggesting they are a recognised technology provider that big public-private partnerships invite in for a defined assay role. Expect a focused, service-oriented contribution rather than overall scientific leadership.

Connected to 67 distinct consortium partners across 14 countries, an unusually wide network for a small company with only two projects. The network is European in character, anchored in the EU pharma and regulatory toxicology research community.

What sets them apart

Few SMEs combine in-house bioanalytical assay development with a track record inside flagship EU safety-science consortia like TransBioLine and RISK-HUNT3R. Signatope offers a rare bridge between commercial assay services and regulatory-grade biomarker qualification work, in a field dominated by either large CROs or academic labs. For a consortium, they are the kind of partner you bring in when you need biomarker measurements that will actually be defensible to regulators.

Highlights from their portfolio

• TransBioLine
  Their largest engagement at EUR 2.25M — a flagship translational safety biomarker initiative that anchors their reputation in drug safety.
• RISK-HUNT3R
  Marks their strategic move from drug safety into next-generation chemical risk assessment using non-animal testing methods.